Partners like these health workers at the MenAfriVac vaccine launch helped MVP develop banks of data and sera that are now available to researchers. Photo: PATH/Amy MacIver.
MVP Access Program open to researchers
The Meningitis Vaccine Project (MVP), a partnership between PATH and the World Health Organization (WHO), in collaboration with Serum Institute of India Private Ltd., resulted in the historic development and large-scale public health use of MenAfriVac®. The introduction of this vaccine has led to the control and near-elimination of deadly meningitis A disease in Africa’s “meningitis belt”.
The clinical trials of MenAfriVac conducted in India and in Africa included an overall total of approximately 11,100 volunteers and generated a significant collection of medical and laboratory data in the MVP database. In addition, the MVP sera bank includes approximately 81,000 remaining vials of sera from the MVP clinical studies conducted in Africa.
Researchers conducting studies related to meningococcal disease and generally on vaccine-preventable diseases can submit research proposals to access the data and/or sera, provided that:
- The proposed research is in the public health interest and does not include genetic research.
- Researchers agree to comply with the laws, regulations, research standards, and ethical standards governing the MVP Clinical Study protocols and informed consents.
To find out more about the available data and sera, and how to submit a proposal, please email firstname.lastname@example.org.
PATH and Serum Institute representatives, in close coordination with representatives of the research sites where the MVP studies were conducted and sera collected, will review all research proposals submitted by qualified investigators and will maintain the list of approved proposals and investigators on this page. Please note that the access program is not a source of funding for submitted research proposals and that researchers can anticipate incurring modest costs for processing and shipping samples.
MVP Access Program’s approved projects
The MVP Access Program allows researchers conducting studies related to meningococcal disease and generally on vaccine-preventable diseases to access the data and/or sera from the MVP clinical studies. MVP is currently reviewing proposals and will list approved projects here as they are confirmed.
MenAfriVac is a registered trademark of Serum Institute of India Private Ltd.